Today's top medical abstracts
Oncology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Oncology
For Practicing
Oncologists
Conferences
Jobs
Newsletters
My Library
Topics in
Oncology
        Alternative Therapies
        Anemia/Polycythemia
        BMT/SCT
        Basic Science/Genetics
        Bone/Cartilage
        Breast
        Carcinogenesis
        Coagulation/Bleeding Dz
        Colorectal Cancer/Polyps
        Dermatologic Oncology
        Diagnostics/Radiology
        Economics of Medicine
        Endocrine Oncology
        GI Oncology
        Gynecologic Oncology
        Head and Neck
        Hepatobiliary/Pancreas
        Leukemia/Lymphoma
        Lung/Thoracic Oncology
        Myeloproliferative Dz
        Neurologic Oncology
        Pain/Palliative Care
        Pediatric Heme/Oncology
        Pharmacology/Therapy
        Popular Press
        Renal/Urologic
        Side Effects
        Soft Tissue/Sarcoma
        Transfusion Medicine
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Oncologists
Improving Your Bottom Line: Mid Year Analysis Vital to Practice
Owen Dahl, Owen Dahl Consulting
FDA Update: Immune Response Robustness Correlates with Survival in Brain Cancer Vaccine Trial
Tracy Hampton, PhD, MDLinx Oncology
  See all
laryngeal  cancer surgical margins; Survivin and CD44v6 Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
Prognostic significance of Survivin and CD44v6 in laryngeal cancer surgical margins
Journal of Cancer Research & Clinical Oncology, 05/16/08
Print     Email This Article     Save in My Library   Free Abstract
Zhao H et al. - In a trial to evaluate the prognostic value of positive Survivin and CD44v6 expression in surgical margin after curative surgery for laryngeal cancer, it was found that immunohistochemical assessment of both Survivin and CD44v6 status in negative surgical margin may be a valuable approach for predicting recurrence and survival after curative surgery for laryngeal cancer

Methods
  • Immunohistochemistry was performed to detect the expression of Survivin and CD44v6 using polyclonal antibody on 112 pair of formalin-fixed, paraffin-embedded laryngeal cancer and negative surgical margin tissue samples
  • Results were compared with data from the prospective registry of laryngeal cancer by univariate and multivariate logistic regression model focusing specifically on recurrence

Results
  • Survivin and CD44v6 expression in surgical margins were documented in 39.3% and 31.3% of pts and were associated with a higher incidence of tumor progression and poorer disease-free survival
  • Multivariate logistic regression analysis demonstrated that Survivin and CD44v6 expression in surgical margin, T-stage, and histological grade were independent predictive factors for recurrence
  • Proportional hazards model identified Survivin and CD44v6 expression in surgical margin, T-stage, and histological grade, as independently related to disease-free survival
  • Using subgroup analysis, it was found that the Survivin+/CD44v6+ subgroup has the poorest prognosis, whereas the Survivin?/CD44v6? subgroup has the best prognosis

 

--- BASIC SCIENCE/GENETICS TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



 

Sponsor
--- HEAD AND NECK TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



Sponsor
Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.